Gastrointestinal stromal tumors

References

1. ↵
   1. Rubin BP,
   2. Heinrich MC,
   3. Corless CL

   (2007) Gastrointestinal stromal tumour. Lancet 369:1731–1741.

   OpenUrlCrossRefPubMedWeb of Science
2. 1. Zhang W

   (2007) Molecular approaches to resolve diagnostic dilemmas:the case of gastrointestinal stromal tumor and leiomyosarcoma. Future Oncol 3:629–637.

   OpenUrlPubMed
3. ↵
   1. Heinrich MC,
   2. Corless CL,
   3. Duensing A,
   4. McGreevey L,
   5. Chen CJ,
   6. Joseph N,
   7. et al.

   (2003) Activating mutations in gastrointestinal stromal tumors. Science 299:708–710.

   OpenUrlAbstract/FREE Full Text
4. ↵
   1. Fletcher CD,
   2. Berman JJ,
   3. Corless C,
   4. Gorstein F,
   5. Lasota J,
   6. Longley BJ,
   7. et al.

   (2002) Diagnosis of gastrointestinal stromal tumors:A consensus approach. Hum Pathol 33:459–465.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   1. Von Mehren M,
   2. Randall RL,
   3. Benjamin RS,
   4. Boles S,
   5. Bui MM,
   6. Casper ES,
   7. et al.

   (2014) Gastrointestinal stromal tumors, version 2.2014:Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 12:853–862.

   OpenUrlAbstract/FREE Full Text
6. ↵
   1. Woodall CE,
   2. Brock GN,
   3. Fan J,
   4. Byam JA,
   5. Scoggins CR,
   6. McMasters KM,
   7. et al.

   (2009) An evaluation of 2537 gastrointestinal stromal tumors for a proposed clinical staging system. Arch Surg 144:670–678.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   1. Kjetil Søreide,
   2. Oddvar M Sandvik,
   3. Jon Arne Søreide,
   4. Vanja Giljaca,
   5. Andrea Jureckova V,
   6. Ramesh Bulusu

   (2016) Global epidemiology of gastrointestinal stromal tumors (GIST):A systemic review of population based cohort studies. Cancer Epidemiology 40:39–46.

   OpenUrl
8. ↵
   1. Demetri GD,
   2. Benjamin RS,
   3. Blanke CD,
   4. Blay JY,
   5. Casali P,
   6. Choi H,
   7. et al.

   (2007) NCCN Task Force. NCCN Task Force report:management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 5(Suppl 2):1–29.

   OpenUrlAbstract/FREE Full Text
9. ↵
   1. Hirota S,
   2. Isozaki K,
   3. Moriyama Y,
   4. Hashimoto K,
   5. Nishida T,
   6. Ishiguro S,
   7. et al.

   (1998) Gain of function mutations of c-Kit in human gastrointestinal stromal tumors. Science 279:577–580.

   OpenUrlAbstract/FREE Full Text
10. ↵
    1. DeMatteo RP,
    2. Lewis JJ,
    3. Leung D,
    4. Mudan SS,
    5. Woodruff JM,
    6. Brennan MF

    (2000) Two hundred gastrointestinal stromal tumors:recurrence patterns and prognostic factors for survival. Ann Surg 231:51–58.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    1. Tryggvason G,
    2. Gislason HG,
    3. Magnusson MK,
    4. Jonasson JG

    (2005) Gastrointestinal stromal tumors in Iceland, 1990-2003:the icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 117:289–293.

    OpenUrlCrossRefPubMedWeb of Science
12. 1. Kim KM,
    2. Kang DW,
    3. Moon WS,
    4. Park JB,
    5. Park CK,
    6. Sohn JH,
    7. et al.

    (2005) Gastrointestinal Stromal Tumor Committee;Korean Gastrointestinal Pathology Study Group. Gastrointestinal stromal tumors in Koreans:it's incidence and the clinical, pathologic and immunohistochemical findings. J Korean Med Sci 20:977–984.

    OpenUrlCrossRefPubMedWeb of Science
13. 1. Chan KH,
    2. Chan CW,
    3. Chow WH,
    4. Kwan WK,
    5. Kong CK,
    6. Mak KF,
    7. et al.

    (2006) Gastrointestinal stromal tumors in a cohort of Chinese patients in Hong Kong. World J Gastroenterol 12:2223–2228.

    OpenUrlPubMedWeb of Science
14. ↵
    1. Steigen SE,
    2. Eide TJ

    (2009) Gastrointestinal stromal tumors (GISTs):a review. APMIS 117:73–86.

    OpenUrlPubMed
15. ↵
    1. Joensuu H,
    2. Vehtari A,
    3. Riihimäki J,
    4. Nishida T,
    5. Steigen SE,
    6. Brabec P,
    7. et al.

    (2012) Risk of recurrence of gastrointestinal stromal tumour after surgery:an analysis of pooled population-based cohorts. Lancet Oncol 13:265–274.

    OpenUrlCrossRefPubMedWeb of Science
16. 1. Raut Chandrajit P,
    2. Pawlik,
    3. Timothy M

    (2014) Gastrointestinal stromal tumors. Current Surgical Therapy, 96–103.
17. ↵
    1. Matthew T Hueman,
    2. Richard D Schulick

    (2008) Management of gastrointestinal stromal tumors. Surgical Clinics of North America 88:599–614.

    OpenUrlCrossRefPubMedWeb of Science
18. ↵
    1. West RB,
    2. Corless CL,
    3. Chen X,
    4. Rubin BP,
    5. Subramanian S,
    6. Montgomery K,
    7. et al.

    (2004) The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 165:107–113.

    OpenUrlCrossRefPubMedWeb of Science
19. 1. Espinosa I,
    2. Lee CH,
    3. Kim MK,
    4. Rouse BT,
    5. Subramanian S,
    6. Montgomery K,
    7. et al.

    (2008) A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol 32:210–218.

    OpenUrlCrossRefPubMedWeb of Science
20. ↵
    1. Lee CH,
    2. Liang CW,
    3. Espinosa I

    (2010) The utility of discovered on gastrointestinal stromal tumor 1 (DOG1) antibody in surgical pathology-the GIST of it. Adv Anat Pathol 17:222–232.

    OpenUrlCrossRefPubMed
21. ↵
    1. Hussa F

    (2011) Al-Hussaini. GIST in Saudi Arabia:Multicenteric histopathological genetic study of 75 surgically excised cases. Med J Cairo Univ 79:167–172.

    OpenUrl